Jiangsu wuzhong(SH:600200) Shang Hai Zheng Quan Bao·2025-10-31 05:51Core Viewpoint - The company faces significant risks of being delisted due to allegations of financial misconduct, including inflated revenue and profits from 2020 to 2023, as identified by the China Securities Regulatory Commission (CSRC) [11][14][15]. Financial Performance - For the first nine months of 2025, the company's aesthetic biomedical business generated revenue of 303.61 million yuan, an increase of 52.78% compared to the previous year [21]. - The pharmaceutical business reported revenue of 468.06 million yuan, a decrease of 55.79% year-on-year, with the pharmaceutical manufacturing segment contributing 345.22 million yuan and the pharmaceutical commerce segment 122.84 million yuan [21]. Regulatory Issues - The company received a notice from the CSRC on July 13, 2025, indicating potential administrative penalties for falsely reporting financial data, which could lead to mandatory delisting [12][14]. - The company has been under investigation since February 26, 2025, for suspected violations of information disclosure laws [13]. Shareholder and Stock Status - The company's controlling shareholder's shares are fully pledged or subject to judicial restrictions, raising concerns about liquidity and control [18]. - The stock has been placed under risk warning due to the ongoing investigation and potential delisting risks [12][16]. Other Operational Risks - The company reported a net loss of 87.47 million yuan for the first three quarters of 2025, a decline of 294.03% compared to the same period last year [18]. - There are unresolved issues regarding non-operational fund occupation by related parties, with significant amounts reported as of the end of 2023 [17].